Elicio Therapeutics (Elicio Therapeutics) Interest Coverage : 0 (At Loss) (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Elicio Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Elicio Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-10.24 Mil. Elicio Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $-0.04 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Elicio Therapeutics's Interest Coverage or its related term are showing as below:

ELTX's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Elicio Therapeutics Interest Coverage Historical Data

The historical data trend for Elicio Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Elicio Therapeutics Interest Coverage Chart

Elicio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

N/A

No Debt

Elicio Therapeutics Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Elicio Therapeutics's Interest Coverage

For the Biotechnology subindustry, Elicio Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicio Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Elicio Therapeutics's Interest Coverage falls into.

Elicio Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Elicio Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Elicio Therapeutics's Interest Expense was $-1.06 Mil. Its Operating Income was $-35.75 Mil. And its Long-Term Debt & Capital Lease Obligation was $6.01 Mil.

Elicio Therapeutics did not have earnings to cover the interest expense.

Elicio Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Elicio Therapeutics's Interest Expense was $-0.04 Mil. Its Operating Income was $-10.24 Mil. And its Long-Term Debt & Capital Lease Obligation was $5.79 Mil.

Elicio Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Elicio Therapeutics (NAS:ELTX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Elicio Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Elicio Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicio Therapeutics (Elicio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicio Therapeutics Inc (NAS:ELTX) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

9HA:Germany

Address

One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA, USA, 02139

Website

https://www.elicio.com

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.

Executives

Yekaterina Chudnovsky	director	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Robert R Ruffolo	director
Peter Demuth	officer: Chief Scientific Officer	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Assaf Segal	director	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Annette Matthies	officer: Chief Business Officer	ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139
Robert Connelly	director, officer: CEO, President and Director	1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Julian Adams	director	C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116
Christopher Haqq	officer: See Remarks	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Carol Gail Ashe	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Brian Piekos	officer: Chief Financial Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Gregory S Curhan	officer: See Remarks	600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Itzhak Goldberg	officer: See Remarks	51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
John F. Neylan	officer: See Remarks	750 LEXINGTON AVENUE, NEW YORK NY 10022